Market Alert: Trump-Xi APEC Summit a Critical Test for Global Trade Stability
Starpharma Holdings Limited (ASX: SPL) is a biotechnology company with more than two decades of expertise in dendrimer technology, a nanoscale platform with wide applications in healthcare. The company develops dendrimer-based products aimed at improving patient outcomes in cancer and other serious illnesses. Its portfolio includes three clinical-stage DEP® (Dendrimer Enhanced Product) assets, preclinical radiopharmaceutical candidates, research collaborations, and several marketed over-the-counter products.
In September 2025, Starpharma announced a research and option agreement with Radiopharm Theranostics (ASX: RAD). This partnership, under Starpharma’s Star Navigator program, will apply the DEP® platform to develop a dendrimer-drug conjugate incorporating Radiopharm’s radiopharmaceutical molecule. The agreement includes R&D service fees, a potential AU$0.5 million option fee, AU$2 million upfront license payment, and up to AU$89 million in milestone payments, plus royalties. This marks Starpharma’s first radiopharmaceutical partnership, broadening its opportunities in targeted cancer therapies
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
